The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Neoadjuvant Radiotherapy

Neoadjuvant Radiotherapy

Neoadjuvant radiotherapy refers to the use of radiation therapy before the primary treatment, such as surgery or chemotherapy.
This approach can help shrink tumors, making them easier to remove and improving the chances of successful treatment.
Neoadjuvant radiotherapy is commonly used for various cancers, including breast, rectal, and lung cancer.
By delivering radiation before the main treatment, this strategy can enhance the effectiveness of the overall therapy plan and optimize patient outcomes.
Researchers and clinicians can leverage PubCompare.ai's AI-driven platform to optimize neoadjuvant radiotherapy protocols, enhance reproducibility, and easily locate the best practices from literature, pre-prints, and patents using intelligent comparisions.
Improve your research results with this powerful tool.

Most cited protocols related to «Neoadjuvant Radiotherapy»

This is a retrospective study using the National Cancer Institute Surveillance, Epidemiology, and End Results Program, a publicly available and deidentified population-based tumor registry covering approximately 28% of the U.S. population.9 The data entry to this database is performed by registered staff personnel with rigorous quality control.10 The institutional review board at the University of Southern California exempted this study as a result of the use of publicly available, deidentified data.
The data set extraction was performed by using SEER*Stat 8.3.2 to use the SEER18 cases for malignancies in “Corpus Uteri/Uterus NOS.” Within the extracted cases, women aged younger than 50 years with stage I endometrioid endometrial cancer diagnosed between 1983 and 2013 who had ovarian conservation at hysterectomy were included in the study cohort. This age cutoff was chosen based on mean age of spontaneous menopause in the North American population.11 (link) Sarcoma or metastatic tumors to the uterus from another origin, no or unknown hysterectomy status, neoadjuvant radiotherapy, no or unknown ovarian conservation status, stage II–IV or unknown stage, nonendometrioid histology types, and age 50 years or older were excluded from the analysis.
To identify the subsequent ovarian cancers, an ovarian cancer data set was generated from the section for malignancies in “Ovary” in the same study period. Then, the ovarian cancer data set was linked with the endometrial cancer data set by sorting according to the unique database identification number. The same study identification numbers between the two data sets were considered secondary primary cancer, as described and validated previously.12 (link)The chronologic time sequence of the endometrial cancer diagnosis date and the ovarian cancer diagnosis date were examined among the secondary primary cancer cases. Then, 1) women in whom primary ovarian cancer was diagnosed before the date of endometrial cancer and 2) women with synchronous endometrial and ovarian cancers were excluded from the study. Ovarian cancers diagnosed 6 months or later after an endometrial cancer diagnosis were considered subsequent ovarian cancers. The cutoff value of a 6-month time interval between the two cancer diagnoses is based on the rationale that endometrial cancer is commonly diagnosed by endometrial sampling before hysterectomy and ovarian cancer is generally diagnosed at the time of subsequent hysterectomy. Nearly 90% of women with endometrial cancer undergo hysterectomy within 4 months of diagnosis.13 (link)-15 (link)Among the eligible cases for analysis, patient demographics, tumor information, treatment patterns, and survival outcome were ascertained from the database. Patient demographics included age, year and month of diagnosis, ethnicity, marital status, and registration area. Tumor information included cancer stage, histologic subtype, tumor grade, and tumor size. For treatment patterns, use of hysterectomy, oophorectomy, pelvic lymphadenectomy, and postoperative radiotherapy was abstracted. For survival, cause-specific survival and overall survival were examined.
Recorded cancer stage was reclassified using the American Joint Committee on Cancer 7th surgical–pathologic staging classification schema.16 The International Classification of Diseases for Oncology, 3rd Revision codes for disease site histology validation and World Health Organization histologic classification were used for grouping histologic subtypes as reported previously.5 (link) Women with surgical codes for hysterectomy without oophorectomy were classified as having undergone ovarian conservation as described previously.5 (link),7 (link),8 (link)Endometrial cancer-specific survival was defined as the time interval between the endometrial cancer diagnosis and the death from endometrial cancer. Overall survival was defined as the time interval between the endometrial cancer diagnosis and the death from any reason (all-cause). This definition was also applied to the ovarian cancer cases. Cause of death in this database is linked with the National Death Index and the state mortality records.17 The primary study endpoint was the cumulative incidence of subsequent ovarian cancer after ovarian conservation in women aged younger than 50 years with stage I endometrioid endometrial cancer. The secondary study objective was to examine tumor characteristics and outcome of subsequent ovarian cancer. Kaplan-Meier method was used to construct cumulative risk curves for subsequent ovarian cancer18 ; and statistical significance between the curves was examined with a log-rank test for univariable analysis. In addition, a Cox proportional hazard regression model was used to estimate hazard ratio (HR) and 95% confidence interval (CI) for subsequent ovarian cancer risk.19 Based on our recent study,5 (link) we estimated eligible cases for this study to be approximately 1,300–1,500. We also assumed the subsequent ovarian cancer risk to be less than 1–2% after ovarian conservation at the time of hysterectomy.20 (link) Thus, we did not perform multivariable analysis because it may result in over-adjustment. All hypotheses were two-tailed, and P<.05 was considered statistically significant. SPSS 24.0 was used for the analysis. The Strengthening the Reporting of Observational Studies in Epidemiology guidelines were used to outline the performance of this observational study.21 (link)
Publication 2017
Diagnosis Endometrial Carcinoma Endometrium Ethics Committees, Research Ethnicity Hysterectomy Joints Lymph Node Excision Malignant Neoplasms Menopause Muscle Rigidity Neoadjuvant Radiotherapy Neoplasms North American People Operative Surgical Procedures Ovarian Cancer Ovariectomy Ovary Patients Pelvis Radiotherapy Sarcoma Second Primary Cancers Uterine Neoplasms Uterus Woman Youth
Patients were recruited from oncology practices in Los Angeles to participate in a longitudinal, observational study of cancer-related fatigue (RISE study). Women were eligible if they had been recently diagnosed with Stage 0-IIIA breast cancer and had not yet started adjuvant or neoadjuvant therapy with radiation, chemotherapy, or endocrine therapy. Primary recruitment sites were UCLA and Cedars Sinai Medical Center (CSMC).
Participants completed assessments at baseline, end of treatment (for those who received radiation and/or chemotherapy), and at 6, 12, and 18 month post-treatment follow-ups; we focus here on the baseline assessment. The Institutional Review Boards at UCLA and CSMC approved the study, and all participants provided written informed consent.
Publication 2018
Ethics Committees, Research Fatigue Malignant Neoplasm of Breast Malignant Neoplasms Neoadjuvant Radiotherapy Neoplasms Patients Pharmaceutical Adjuvants Pharmacotherapy Radiotherapy System, Endocrine Woman
The Northern Ireland Cancer Registry was used to identify 1426 stage II and III colon cancer patients undergoing surgical resection between 2004 and 2008 (Figure 1). Rectal cancers were excluded as neoadjuvant radiotherapy could potentially alter tumour expression profiles. Ethical approval through the Northern Ireland Biobank (NIB reference number 13–0087) permitted retrieval of formalin-fixed, paraffin-embedded (FFPE) tissue blocks for patients within two of the five regional Health and Social Care trusts. For this molecular pathological epidemiology study, the final cohort was subsequently restricted to only include patients within the biobank remit (n=740, 51.9%). These patients were representative of the overall Northern Ireland cohort with respect to age, sex, stage, and adjuvant chemotherapy receipt (Supplementary Table 1).
Publication 2017
Cancer of Colon Cardiac Arrest Chemotherapy, Adjuvant Formalin Malignant Neoplasms Neoadjuvant Radiotherapy Neoplasms Operative Surgical Procedures Paraffin Embedding Rectal Cancer
RSEM normalized expression data was extracted into Microsoft Excel and the HPV status was manually curated based on published datasets as described.47 Primary patient samples with known HPV status were grouped as HPV+, HPV-, or normal control tissue. This classification agrees completely with work done by others41, with the exception of sample TCGA-BB-7862‐01A. That sample had minimal reads aligning to the HPV genome, none of which aligned to the HPV16 E6 or E7 oncogenes, and we classified this sample as HPV- rather than HPV+ . Patient samples with unknown HPV status were omitted from our calculations, as were samples obtained from secondary metastatic lesions. This resulted in 73 HPV+, 442 HPV-, and 43 normal control samples with data available for the HNSCC gene expression analysis. This surgically managed cohort was considered treatment-naïve, as only 9 patients received neoadjuvant radiation or chemotherapy treatment (2 HPV+, 7 HPV-). Boxplot comparison of gene expression was performed using GraphPad Prism v7.0 (Graphpad Software, Inc., San Diego, California, USA) and assembled into final form using CorelDRAW (Corel, Ottawa, Ontario, Canada). For the boxplots, center lines show the medians, box limits indicate the 25th and 75th percentiles as determined by Graphpad Prism, and whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles. Statistical significance was calculated using Graphpad Prism. P-values were assigned using a one-tailed non-parametric Mann-Whitney U test. Selected genes were compared in a pairwise fashion and concordance calculated using Spearman’s Rho analysis. Differences were considered to be statistically significant for P < 0.05.
Publication 2018
E6 protein, Human papillomavirus type 16 Gene Expression Gene Expression Profiling Genes Genome Neoadjuvant Radiotherapy Oncogenes Operative Surgical Procedures Patients Pharmacotherapy prisma Squamous Cell Carcinoma of the Head and Neck Tissues Venous Catheter, Central Vibrissae
Patients were recruited from oncology practices in Los Angeles to participate in a longitudinal, observational study of cancer-related fatigue (RISE study). Women were eligible if they had been recently diagnosed with Stage 0-IIIA breast cancer, had not yet started adjuvant or neoadjuvant therapy with radiation, chemotherapy, or endocrine therapy, and were English proficient. Primary recruitment sites were UCLA and Cedars Sinai Medical Center (CSMC).
Participants completed assessments at baseline, end of treatment (for those who received radiation and/or chemotherapy), and at 6, 12, and 18-month post-treatment follow-ups. The majority of women (91%) had completed surgery (lumpectomy or mastectomy) at the time of enrollment; the remaining 9% were enrolled before neoadjuvant therapy and thus had not had surgery at baseline. The Institutional Review Boards at UCLA and CSMC approved the study, and all participants provided written informed consent.
Publication 2021
Ethics Committees, Research Fatigue Lumpectomy Malignant Neoplasm of Breast Malignant Neoplasms Mastectomy Neoadjuvant Radiotherapy Neoadjuvant Therapy Neoplasms Operative Surgical Procedures Patients Pharmaceutical Adjuvants Pharmacotherapy Radiotherapy System, Endocrine Woman

Most recents protocols related to «Neoadjuvant Radiotherapy»

The study was conducted in accordance with the Helsinki Declaration (as revised in 2013). This study was approved by the Ethics Committee of Weifang People's Hospital. All patients consented to data being used for research when receiving treatment. Inclusion criteria were as follows: Aged 18 to 80, gastroscopic biopsy-confirmed gastric cancer, pathological staging (pT1∼4aN0∼3M0), obtain informed consent of patients. Exclusion criteria were as follows:received neoadjuvant radiotherapy and chemotherapy prior to surgery, Palliative surgery, history of other primary malignacies, incomplete information or loss to follow-up. A flowchart of the study is shown in Figure 1.
The study protocol was approved by the research ethics committee of Weifang People's Hospital. Written informed consent was obtained from all patients prior to surgery. Each patient signed an informed consent to allow their treatment-related information to be used in future studies.
Full text: Click here
Publication 2023
Biopsy Ethics Committees, Clinical Ethics Committees, Research Gastric Cancer Gastroscopy Neoadjuvant Radiotherapy Operative Surgical Procedures Palliative Surgery Patients Pharmacotherapy
Circumferential resection margin (CRM) was defined as negative if the distance of the tumor from the margin was more than 1 mm. Histopathological tumor regression to neoadjuvant radiotherapy was evaluated according to the Dworak scoring system (15 (link)). The quality of the TME was evaluated using the protocol introduced by Quirke (16 ).
Full text: Click here
Publication 2023
Neoadjuvant Radiotherapy Neoplasms Surgical Margins
Between March 2018 and July 2021, 26 patients were treated with the concept of neoadjuvant radiotherapy (5 × 5 Gy) and delayed surgery (SRT-delay) for rectal cancer at Ruppin- Brandenburg University Hospital. All patients had locally advanced primary adenocarcinoma (≥uT3 or/and N+) in the lower or middle third of the rectum. In addition, patients with locally advanced upper third rectal cancer whose main tumor mass appeared caudal to the promontory on sagittal MRI view were included.
Patients were assigned to this form of neoadjuvant therapy because they either could not tolerate conventional neoadjuvant chemoradiation due to their comorbidities or refused chemotherapy.
Short-term neoadjuvant radiotherapy included five fractions of 5 Gy in one week (5 × 5 Gy), followed by an interval of about 8 weeks before surgery.
22 of the 26 patients underwent initial staging (CT, endoscopy, MRI) and complete re-staging before surgery. 4 of 26 patients had to be excluded from the study because of insufficient re-staging. In 2 of these 4 cases, inserted hip arthroplasties caused poor MRI quality. MRI was not possible in one patient, and re-staging endoscopy was not performed in the remaining patient.
The clinical data of the 22 patients enrolled in the study are shown in Table 1.
The study was approved by the ethics committee of the Brandenburg Medical School (No. E-02-20210930).
Tumor downsizing after neoadjuvant therapy was assessed by comparing staging and re-staging data on MRI and endoscopy and by comparing initial staging data with pathological findings.
Full text: Click here
Publication 2023
Adenocarcinoma Arthroplasty Endoscopy, Gastrointestinal Ethics Committees Neoadjuvant Chemoradiotherapy Neoadjuvant Radiotherapy Neoadjuvant Therapy Neoplasms Operative Surgical Procedures Patients Pharmacotherapy Rectal Cancer Rectum
We performed a retrospective analysis of all patients who underwent interdisciplinary surgical therapy for extremity soft-tissue sarcoma at our University Hospital in 2021. A total of 31 patients were included. The inclusion criteria for this analysis were a histologically confirmed diagnosis of extremity STS and treatment at our Center. Patients with abdominal, retroperitoneal, thoracal and trunk soft-tissue sarcoma were excluded. Data including patient characteristics (median age and sex), treatment characteristics (neoadjuvant radiotherapy, neoadjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemotherapy), sarcoma characteristics (tumor location, tumor size, sarcoma subtype), surgical treatment after tumor resection (e.g., primary wound closure, flap), follow up and complications after surgical therapy (in the subgroup of primary wound closure, primary flap reconstruction, secondary flap reconstruction) were extracted by reviewing digital medical records.
Full text: Click here
Publication 2023
Abdomen Chemotherapy, Adjuvant Diagnosis Fingers Neoadjuvant Chemotherapy Neoadjuvant Radiotherapy Neoplasms Neoplasms by Site Operative Surgical Procedures Patients Radiotherapy, Adjuvant Reconstructive Surgical Procedures Retroperitoneal Space Sarcoma Surgical Flaps Therapeutics Therapy, Soft Tissue Wounds
We collected primary tumor tissues and paired normal colorectal tissues (> 5 cm distance from the cancer tissue margin) from 40 CRC patients from the Zhongnan Hospital of Wuhan University (Wuhan, China). All enrolled patients were definitively diagnosed with colorectal adenocarcinoma by histopathology, and none had received neoadjuvant radiotherapy or/and chemotherapy before undergoing resection. In addition, all the enrolled patients in the group had corresponding available survival data. This study was endorsed by the Ethics Committee of Zhongnan Hospital of Wuhan University in compliance with the Declaration of Helsinki. Informed consent was obtained from all the patients before sample collection.
Full text: Click here
Publication 2023
Adenocarcinoma Ethics Committees, Clinical Inpatient Malignant Neoplasms Neoadjuvant Radiotherapy Neoplasms Patients Pharmacotherapy Specimen Collection Tissues

Top products related to «Neoadjuvant Radiotherapy»

Sourced in United States
TomoTherapy is a radiation therapy system designed for the treatment of cancer. It utilizes a linear accelerator that rotates around the patient, delivering precise and targeted radiation. The system combines imaging and treatment planning capabilities to enable accurate and efficient delivery of radiation therapy.
Sourced in United States, China, Germany, Japan, France, Poland, Australia, Israel, United Kingdom, Italy
The SW480 is a laboratory equipment product from the American Type Culture Collection (ATCC). It is a colorectal adenocarcinoma cell line that can be used for various cell-based research applications.
Sourced in United States, United Kingdom, Germany, Japan
The Signa HDx is a magnetic resonance imaging (MRI) system developed by GE Healthcare. It is designed to provide high-quality imaging for a wide range of clinical applications. The Signa HDx utilizes advanced technology to deliver optimal image quality and performance.
Sourced in Canada, United States, China, Sao Tome and Principe, United Kingdom, Macao
Fetal Bovine Serum (FBS) is a complex biological mixture derived from the blood of bovine fetuses. It is a commonly used supplement in cell culture media, providing essential growth factors, proteins, and other nutrients to support the growth and proliferation of various cell types.
Sourced in United States, Germany, United Kingdom, Japan, Lithuania, France, Italy, China, Spain, Canada, Switzerland, Poland, Australia, Belgium, Denmark, Sweden, Hungary, Austria, Ireland, Netherlands, Brazil, Macao, Israel, Singapore, Egypt, Morocco, Palestine, State of, Slovakia
The High-Capacity cDNA Reverse Transcription Kit is a laboratory tool used to convert RNA into complementary DNA (cDNA) molecules. It provides a reliable and efficient method for performing reverse transcription, a fundamental step in various molecular biology applications.
Sourced in United States, United Kingdom, Japan, Austria
SPSS Statistics for Windows, Version 24.0 is a comprehensive software package for statistical analysis. It provides a wide range of statistical procedures for data management, analysis, and presentation. The software is designed to handle complex data structures and offers a user-friendly interface for conducting statistical analysis.
Sourced in Sweden, United Kingdom, Canada
A linear accelerator is a type of medical device used to deliver high-energy radiation for the treatment of cancer. It accelerates charged particles, typically electrons, and directs the resulting beam of radiation towards the tumor or target area in the patient's body.
Sourced in United States, Germany, United Kingdom, China, France
Caco-2 is a continuous cell line derived from a human colorectal adenocarcinoma. It is a model for intestinal epithelial cells and is commonly used in studies involving drug absorption, transport, and permeability.
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Austria, Italy, Poland, India, Canada, Switzerland, Spain, China, Sweden, Brazil, Australia, Hong Kong
SPSS Statistics is a software package used for interactive or batched statistical analysis. It provides data access and management, analytical reporting, graphics, and modeling capabilities.
Sourced in United States, China
The NCM460 is a cell line provided by the American Type Culture Collection (ATCC). It is a normal, non-transformed human colon mucosal epithelial cell line that can be used for in vitro studies.

More about "Neoadjuvant Radiotherapy"

Neoadjuvant radiotherapy, also known as preoperative radiotherapy, refers to the use of radiation therapy before the primary treatment, such as surgery or chemotherapy.
This approach can help shrink tumors, making them easier to remove and improving the chances of successful treatment.
Neoadjuvant radiotherapy is commonly used for various cancers, including breast, rectal, and lung cancer.
By delivering radiation before the main treatment, this strategy can enhance the effectiveness of the overall therapy plan and optimize patient outcomes.
Researchers and clinicians can leverage PubCompare.ai's AI-driven platform to optimize neoadjuvant radiotherapy protocols, enhance reproducibility, and easily locate the best practices from literature, pre-prints, and patents using intelligent comparisons.
This powerful tool can help improve research results by providing access to a wealth of information on neoadjuvant radiotherapy, including related terms like TomoTherapy, SW480, Signa HDx, FBS, High-Capacity cDNA Reverse Transcription Kit, SPSS Statistics for Windows, Version 24.0, Linear accelerator, Caco-2, SPSS Statistics, and NCM460.
By utilizing PubCompare.ai's platform, researchers can ensure their neoadjuvant radiotherapy protocols are based on the latest best practices and optimize their chances of success.
The tool's intelligent comparison capabilities allow users to easily identify the most effective protocols from a vast pool of literature, pre-prints, and patents, helping to enhance the reproducibility and effectiveness of their research.
With PubCompare.ai, researchers can take their neoadjuvant radiotherapy studies to the next level and achieve better outcomes for their patients.